Exploratory analysis of serum concentrations of oocyte biomarkers growth differentiation factor 9 and bone morphogenetic protein 15 in ovulatory women across the menstrual cycle.

Autor:	Riepsamen AH; Fertility and Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, New South Wales, Australia. Electronic address: a.riepsamen@unsw.edu.au., Donoghoe MW; Stats Central, Mark Wainwright Analytical Centre, University of New South Wales Sydney, New South Wales, Australia., Baerwald A; Department of Academic Family Medicine, West Winds Primary Health Center, Saskatchewan, Canada; College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada., Pankhurst MW; Department of Anatomy, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand., Lien S; Fertility and Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, New South Wales, Australia., Chong YH; Department of Anatomy, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand., Robertson DM; Fertility and Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, New South Wales, Australia., Ledger WL; Fertility and Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, New South Wales, Australia., Gilchrist RB; Fertility and Research Centre, School of Women's and Children's Health, University of New South Wales Sydney, New South Wales, Australia.
Jazyk:	angličtina
Zdroj:	Fertility and sterility [Fertil Steril] 2021 Aug; Vol. 116 (2), pp. 546-557. Date of Electronic Publication: 2021 Mar 26.
DOI:	10.1016/j.fertnstert.2021.02.001
Abstrakt:	Objective: To characterize and evaluate the variation in serum concentrations of oocyte-secreted growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) throughout the menstrual cycle in women from young to advanced reproductive ages. Design: Cross-sectional, observational, and exploratory study. Setting: Multicenter university-based clinical practices and laboratories. Patient(s): Serum was collected every 1-3 days throughout the menstrual cycle from 3 cohorts of healthy, ovulatory women: menses to late luteal phase (21-29 years of age; n = 16; University of Otago) and across one interovulatory interval (18-35 years of age; n = 10; and 45-50 years of age; n = 15; University of Saskatchewan). Intervention(s): None. Main Outcome Measure(s): To detect the changes in serum GDF9 and BMP15 across the cycle, mean concentration and variance were statistically modeled using a generalized additive model of location, shape and scale (GAMLSS). Follicle-stimulating hormone, luteinizing hormone, estradiol, progesterone, and anti-Müllerian hormone were also assessed. Result(s): GDF9 and BMP15 were detectable in 54% and 73% of women and varied 236-fold and 52-fold between women, respectively. Across the menstrual cycle, there were minimal changes in GDF9 or BMP15 within a woman for all cohorts, with no significant differences detected in the modeled mean concentrations. However, modeled variances were highest in the luteal phases of all women for BMP15 immediately after ovulation, regardless of age. Conclusion(s): Serial changes in GDF9 or BMP15 concentrations across the cycle were not statistically detected and are likewise similar across the reproductive lifespan. Further research is required to fully elucidate the utility of these oocyte biomarkers at diagnosing fertility potential and/or disease. (Copyright © 2021 American Society for Reproductive Medicine. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu